Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.81
Bid: 0.00
Ask: 19.96
Change: 0.00 (0.00%)
Spread: 1.32 (7.082%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 18.81
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Response to Shareholder Letter

19 May 2023 13:00

RNS Number : 0649A
Nanoco Group PLC
19 May 2023
 

19 May 2023

NANOCO GROUP PLC

("Nanoco", the "Company" or the "Group")

 

Response to Shareholder Letter

 

Nanoco notes the contents of a second letter that has been circulated to shareholders by Tariq Hamoodi. This follows Mr Hamoodi's letter issued via RNS Reach in March, which has since been removed from the LSE's website.

Nanoco has sought to engage with Mr Hamoodi, including responding to his initial letter. A copy of Nanoco's letter to Mr Hamoodi is available here http://www.rns-pdf.londonstockexchange.com/rns/0649A_1-2023-5-19.pdf.

Nanoco's Board continues to emphatically reject Mr Hamoodi's speculative concerns about certain actions and activities involving Nanoco, and does not believe the proposed Board changes are in the best interests of shareholders.

As previously announced, the Directors of Nanoco have no intention of stepping down from the Board and are confident that the Board's actions and statements over the period of the Samsung litigation were in line with its corporate governance duties, obligations and standards.

Christopher Richards, Non-Executive Chairman of Nanoco, said

"We continue to emphatically reject Mr Hamoodi's speculative concerns. The Board welcomes scrutiny, but his misinterpretation of the past, and consciously selective and factually inaccurate disclosure, including the publication of heavily edited videos, presents a number of events out of context to create a false narrative to mislead our shareholders.

"The proposed Board changes are not in the best interests of the Company or its shareholders, and would give undue influence to a disgruntled minority shareholder. Nanoco is at an exciting inflection point, with the litigation proceeds fully underpinning our organic business which has significant growth opportunities.

"Mr Hamoodi's proposals would be damaging and disruptive to Nanoco's future prospects and, if successful, would result in an exodus of key talent from the business."

 

- Ends -

For further information, please contact:

Nanoco Group PLC:

Dr Christopher Richards, Non-Executive Chairman

Brian Tenner, CEO +44(0)1928761404

Liam Gray, CFO & Company Secretary

 

Peel Hunt (Joint Corporate Broker):

Paul Gillam +44 (0) 20 7418 8900

James Smith

 

Turner Pope Investments (Joint Corporate Broker):

Andrew Thacker +44 (0) 20 3657 0050

James Pope

 

MHP: +44 (0) 203 128 8570

Reg Hoare

Pete Lambie

Veronica Farah

nanoco@mhpgroup.com

 

 

Notes for editors:

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots and other nano-materials. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display, Sensor and Electronics markets. An interesting property of quantum dots is size-tunable absorption spectrum. Nanoco's HEATWAVE™ quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectrum, rendering them useful for applications including image sensors. Another interesting property of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco was founded in 2001 and is headquartered in Runcorn, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information, please visit: www.nanocotechnologies.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RSPBBGDUGUBDGXC
Date   Source Headline
1st Aug 20237:13 amRNSTotal Voting Rights
28th Jul 20235:23 pmRNSDirector/PDMR Shareholding
25th Jul 20232:55 pmRNSPublication of Shareholder Presentation
25th Jul 202312:52 pmRNSNanoco Group Plc
24th Jul 20237:00 amRNSHigh Court Confirmation of Capital Reduction
20th Jul 20237:00 amRNSNotification of Investor Presentation
18th Jul 20237:00 amRNSPosting of Circular and Notice of General Meeting
7th Jul 202311:23 amRNSGeneral Meeting - Voting Results
28th Jun 20237:00 amRNSReceipt of General Meeting Requisition Notice
20th Jun 20237:00 amRNSPosting of Circular and Notice of General Meeting
9th Jun 20237:00 amRNSBlocklisting Six-Monthly Return
19th May 20231:00 pmRNSResponse to Shareholder Letter
21st Apr 20236:00 pmRNSHolding(s) in Company
30th Mar 202311:46 amRNSHolding(s) in Company
28th Mar 20237:00 amRNSInterim Results
27th Mar 20231:19 pmRNSResponse to Shareholder Letter
23rd Mar 20238:40 amRNSNotice of Results
9th Mar 20233:11 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSHolding(s) in Company
3rd Feb 20237:15 amRNSTrading Update
3rd Feb 20237:15 amRNSLitigation Settlement Update
18th Jan 202311:35 amRNSHolding(s) in Company
16th Jan 202312:45 pmRNSHolding(s) in Company
11th Jan 20232:40 pmRNSHolding(s) in Company
10th Jan 20232:37 pmRNSHolding(s) in Company
9th Jan 20237:00 amRNSLitigation Settlement Update
6th Jan 20237:00 amRNSLitigation Outcome – Settlement Agreed
4th Jan 20233:31 pmRNSHolding(s) in Company
20th Dec 20223:51 pmRNSHolding(s) in Company
20th Dec 20222:59 pmRNSResult of AGM
20th Dec 20227:00 amRNSAGM Statement
13th Dec 20227:00 amRNSBlock listing Six-monthly Return
9th Dec 20227:00 amRNSLitigation Update - Firm Trial Date
14th Nov 202210:46 amRNS2022 Annual Report and Notice of AGM
7th Nov 20224:13 pmRNSHolding(s) in Company
27th Oct 20225:19 pmRNSDirector/PDMR Shareholding
26th Oct 20222:31 pmRNSLitigation Update – Funded Law Suit Filed in China
20th Oct 20227:00 amRNSPreliminary Results
14th Oct 202212:59 pmRNSPresentation via Investor Meet Company
14th Oct 202210:41 amRNSNotice of Results
28th Sep 20227:00 amRNSLitigation Update – Further Revised Trial Date
12th Sep 20228:25 amRNSTrading Update & Directorate Change
7th Sep 20223:47 pmRNSLitigation Update – Revised Trial Date
1st Sep 202210:22 amRNSDirector/PDMR Shareholding
31st Aug 20227:00 amRNSTwo Grant Funding Awards
30th Aug 20223:33 pmRNSHolding(s) in Company
30th Aug 20223:28 pmRNSDirector/PDMR Shareholding
25th Aug 20221:36 pmRNSDirector/PDMR Shareholding
23rd Aug 20222:22 pmRNSFunded Law Suit Filed in Germany

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.